

Acknowledgements

We wish to thank the personnel of the Saint-Luc Bouge laboratory for its technical assistance.

Author contributions

FJ, CE, ME, JD, JMD performed the research; FJ, CE, ME, JD, JMD designed the research study, Roche Diagnostics contributed essential reagents or tools; FJ, CE, ME, CG, KL, PG, FJ, JD and JMD analysed the data; FJ, JD and JMD wrote the paper.

Conflict of interest

Among the authors, Jonathan Douxfils is chief executive officer and founder of QUALblood sa and reports personal fees from Diagnostica Stago, Roche, Roche Diagnostics, Daiichi-Sankyo and Portola, outside the submitted work. Roche Diagnostics generously provided the kits for the validation.

Julien Favresse^{1,2} 

Christine Eucher¹

Marc Elsen¹

Carlos Graux³

Paul Goebels⁴

Kim Laffineur¹

Jean-Baptiste Nicolas⁵

Jean-Michel Dogné²

Jonathan Douxfils^{2,6} 

¹Department of Laboratory Medicine, Clinique St-Luc Bouge, ²Department of Pharmacy, Namur Research Institute for Lifes Sciences, University of Namur, Namur, ³Department of Hematology, CHU UCL

Namur, Yvoir, ⁴Department of Laboratory Medicine, Saint Nikolaus Hospital, Eupen, ⁵Department of Internal Medicine, Clinique St-Luc

Bouge, Namur and ⁶Qualblood sa, Namur, Belgium.

E-mail: j.favresse@labstluc.be

Keywords: COVID-19, SARS-CoV-2, serology, kinetics, symptom onset

First published online 9 July 2020

doi: 10.1111/bjh.16954

References

- Baumann T, Delgado J, Montserrat E. CLL and COVID-19 at the Hospital Clinic of Barcelona: an interim report. *Leukemia*. 2020. <https://doi.org/10.1038/s41375-020-0870-5>
- COVID-19 and CLL: Frequently Asked Questions. <https://www.hematology.org/covid-19/covid-19-and-ctl> Accessed June 4, 2020.
- Winter AK, Hegde ST. The important role of serology for COVID-19 control. *Lancet Infect Dis*. 2020. [https://doi.org/10.1016/S1473-3099\(20\)30322-4](https://doi.org/10.1016/S1473-3099(20)30322-4).
- Long QX, Liu BZ, Deng HJ, Wu GC, Deng K, Chen YK, et al. Antibody responses to SARS-CoV-2 in patients with COVID-19. *Nat Med*. 2020;**26**(6):845–8.
- Farnsworth CW, Anderson NW. SARS-CoV-2 serology: much hype, little data. *Clin Chem*. 2020. <https://doi.org/10.1093/clinchem/hvaa107>
- Favresse J, Eucher C, Elsen M, Marie TH, Dogne JM, Douxfils J. Clinical performance of the Elecsys electrochemiluminescent immunoassay for the detection of SARS-CoV-2 total antibodies. *Clin Chem*. 2020. <https://doi.org/10.1093/clinchem/hvaa131>
- Lippi G, Plebani M. Laboratory abnormalities in patients with COVID-19 infection. *Clin Chem Lab Med*. 2020;**58**(7):1131–4.
- Tang MS, Hock KG, Logsdon NM, Hayes JE, Gronowski AM, Anderson NW, et al. Clinical performance of the Roche SARS-CoV-2 serologic assay. *Clin Chem*. 2020. <https://doi.org/10.1093/clinchem/hvaa132>
- Riches JC, Gribben JG. Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications. *Hematol Oncol Clin North Am*. 2013;**27**:207–35.
- Dhalla F, Lucas M, Schuh A, Bhole M, Jain R, Patel SY, et al. Antibody deficiency secondary to chronic lymphocytic leukemia: should patients be treated with prophylactic replacement immunoglobulin? *J Clin Immunol*. 2014;**34**:277–82.
- Levinson AI. *The impact of malignancy on adaptive immunity*. Stiehm's *Immune Deficiencies*. Cambridge, MA: Academic Press. 2014; p. 875–87.
- Kalpadakis C, Pangalis GA, Sachanas S, Vassilakopoulos TP, Kyriakaki S, Korkolopoulou P, et al. New insights into monoclonal B-cell lymphocytosis. *Biomed Res Int*. 2014;**2014**:258917.

Successful remission induction therapy with gilteritinib in a patient with *de novo* FLT3-mutated acute myeloid leukaemia and severe COVID-19

The optimal treatment for patients with newly diagnosed acute myeloid leukaemia (AML) who are infected with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)/coronavirus disease 2019 (COVID-19) is unknown.¹ We report the case of a previously fit 27-year-old male who presented with a 3-day history of fever (>39°C), swollen, erythematous elbows and no respiratory symptoms. His white blood cell count

(WBC) was $187 \times 10^9/l$ and bone marrow (Fig 1A,C) examination revealed normal karyotype AML with a fms related receptor tyrosine kinase 3 (FLT3) internal tandem duplication (ITD), wild-type nucleophosmin 1 (NPM1) and no additional mutations on a next-generation sequencing panel.

Hyperleucocytosis was immediately treated with hydroxycarbamide, dexamethasone, rasburicase (for tumour lysis




Fig 1. Full blood count parameters are shown in Panel A; white blood cell count (WBC, reference range $3-10 \times 10^9/l$), neutrophils ($2-7.5 \times 10^9/l$) and platelets ($150-400 \times 10^9/l$). Gilteritinib administration (120 mg once daily), starting from day 3 onwards, is indicated by blue bars. The patient presented with high D-dimers >80 mg/l (range <0.5 mg/l; Panel B) and hypofibrinogenaemia (range $1.5-4$ g/l), followed by a hyperfibrinogenaemic stage during which C-reactive protein (CRP; range <5 mg/l, Panel B) peaked. Mild tumour lysis syndrome developed with a near doubling of baseline creatinine (range $66-112$ $\mu\text{mol/l}$; Panel B). Morphological analysis of the bone marrow smear at diagnosis (Panel C, top pane) showed heavy infiltration by myelomonocytic blasts, which were positive for CD34, CD117, human leucocyte antigen DR isotype (HLA-DR), CD33, CD15, CD38, cytoplasmic myeloperoxidase and weakly positive for CD7 by flow cytometry (not shown). The post-induction bone marrow smear showed morphological (Panel C, bottom pane) and flow cytometric complete remission. The initial high-resolution CT (HRCT) scan on day 6 (Panel D, top pane) displays patchy infiltrates with extensive patchy areas of ground glass opacification and 'crazy paving' pattern, typical of severe COVID-19. Repeat HRCT at day 39 (bottom pane) showed widespread ground glass opacification, as well as areas of consolidation and a progressive left-sided pleural effusion.

syndrome prophylaxis), and three doses of 100 mg/m^2 cytarabine over the first 48 h. He received antibiotics to treat febrile neutropenia and cellulitis and although he denied any respiratory symptoms, a combined nasal and pharyngeal swab for SARS-CoV-2 RNA was positive. Doppler ultrasound revealed a lower-limb deep vein thrombosis, bilateral upper-arm superficial thrombophlebitis and coagulation markers were indicative of disseminated intravascular coagulation (Fig 1B). Given his active SARS-CoV-2 infection and the presence of a *FLT3*-ITD mutation, he was treated with single-agent gilteritinib, an oral *FLT3* inhibitor,² from day 3. Gilteritinib shows superior efficacy to salvage chemotherapy in relapsed/refractory *FLT3*-mutated AML,³ with low rates of

infection and early mortality, although it is not currently licensed for use in *de novo* AML.

On day 6, he became hypoxic, with hyperpyrexia, rising C-reactive protein (CRP; Fig 1B), and a high-resolution computed tomography (HRCT) scan of the chest (Fig 1D) showed changes typical for COVID-19. He was transferred to the intensive care unit on day 7 for continuous positive airway pressure (CPAP) support, but deteriorated further on day 13, requiring emergency intubation due to adult respiratory distress syndrome. Dexamethasone was briefly restarted on day 14 to preventatively treat early differentiation syndrome.² He was extubated to CPAP on day 20; however, he experienced a febrile episode associated with seizures on day

22 due to *Escherichia coli* bacteraemia, which precipitated re-intubation, vasopressor support and further antibiotics. Gilteritinib was temporarily discontinued for 7 days from day 25 (Fig 1A) due to biochemical features of septic shock-related cardiomyopathy.

During the admission, the patient experienced only 5 days of severe neutropenia ($<0.5 \times 10^9/l$) and 17 days of thrombocytopenia ($<50 \times 10^9/l$). Post-induction bone marrow examination showed morphological (Fig 1C) complete remission and a significant reduction in *FLT3*-ITD allele ratio from 0.66 at diagnosis to 0.07. He received a tracheostomy without incident on day 33. A repeat HRCT on day 39 (Fig 1D) showed extensive changes associated with severe COVID-19. He was decannulated on day 45 and transferred back to the ward for intensive rehabilitation. SARS-CoV-2 RNA remained detectable on weekly nasopharyngeal swabs until day 60 when it became undetectable. At the time of writing, he continues on gilteritinib, with a plan to proceed to allogeneic stem cell transplantation when he is physically fit.

Though the effects of SARS-CoV-2 infection on patients with AML are largely unknown,¹ early evidence suggests that patients with active haematological malignancies and COVID-19 have more severe disease and a higher case fatality rate.^{4,5} Provisional guidance^{1,6} recommends delaying AML induction chemotherapy in patients with concurrent COVID-19, an option not possible in this case. Induction mortality rates with intensive chemotherapy in those with hyperleucocytosis can approach 30% and such chemotherapy is associated with prolonged pancytopenia (often >3 weeks) and high rates of severe infections.⁷ We conclude that single-agent gilteritinib can be safely administered and induce remission in patients presenting with *de novo FLT3*-ITD-positive AML. Although further studies are required in this setting, gilteritinib can be considered as a treatment option for patients with *FLT3*-mutated AML and severe COVID-19, where a prolonged period of chemotherapy-induced pancytopenia could adversely affect outcomes.

Acknowledgements

Andrew J. Wilson, Ethan Troy-Barnes, Maryam Subhan, Fiona Clark, Rajeev Gupta, Adele K. Fielding, Panagiotis Kottaridis, Marc R Mansour, Jenny O'Nions, Elspeth Payne, Kirsty Thomson and Asim Khwaja provided clinical care for the patient and were involved in critically revising the manuscript. Naina Chavda and Robert Baker provided expert assistance in diagnostics and critically revising the manuscript. All authors have approved the final manuscript.

Conflicts of interest

Andrew J. Wilson: personal fees from Novartis; Marc R. Mansour: advisory boards for Janssen; Elspeth Payne:

advisory boards for Novartis, Celgene and Takeda; Asim Khwaja: personal fees from Astellas, outside the submitted work.

The other authors have no conflicts of interest to declare.

Andrew J. Wilson^{1,3} 

Ethan Troy-Barnes¹

Maryam Subhan¹

Fiona Clark¹

Rajeev Gupta^{1,2,3} 

Adele K. Fielding^{1,2} 

Panagiotis Kottaridis¹

Marc R. Mansour^{1,2} 

Jenny O'Nions^{1,3} 

Elspeth Payne^{1,2} 

Naina Chavda³

Robert Baker³

Kirsty Thomson¹

Asim Khwaja^{1,2,3}

¹Department of Haematology, University College London Hospital (UCLH), ²Department of Haematology, University College London Cancer Institute, and ³UCLH Specialist Integrated Haematology Malignancy Diagnostic Service, Health Services Laboratories, London, UK.
E-mail: andrew.wilson19@nhs.net

First published online 19 July 2020

doi: 10.1111/bjh.16962

References

- Paul S, Rausch C, Jain N, Kadia T, Ravandi F, DiNardo CD, et al. Treating leukemia in the time of COVID-19. *Acta Haematol.* 2020;1–13. <https://doi.org/10.1159/000508199>
- Levis M, Perl AE. Gilteritinib: potent targeting of *FLT3* mutations in AML. *Blood Adv.* 2020;4:1178–91.
- Perl, AE, Martinelli, G, Cortes, JE, Neubauer, A, Berman, E & Paolini, S, et al. Gilteritinib or chemotherapy for relapsed or refractory *FLT3*-mutated AML. *N Engl J Med.* 2019;381:1728–40.
- He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. *Leukemia.* 2020;34:1637–45.
- Martín-Moro, F, Marquet, J., Piris, M., Michael, B.M., Sáez, A.J. & Corona, M. et al. Survival study of hospitalized patients with concurrent Covid-19 and haematological malignancies. *Br J Haematol.* 2020;190 1:e16–20. <https://doi.org/10.1111/bjh.1680>
- NCRI AML Working Party. Recommendations for the management of patients with AML during the COVID19 outbreak: a statement from the NCRI AML Working Party [online]. 2020. Available from: <http://www.cureleukaemia.co.uk/page/news/523/aml-working-party-covid-19-recommendations>. Accessed 09/05/2020.
- Norgaard M, Larsson H, Pedersen G, Schönheyder HC, Sørensen HT. Risk of bacteraemia and mortality in patients with haematological malignancies. *Clin Microbiol Infect.* 2006;12:217–23.